(Q37256821)

19 August 2017

1 reference

title

Nuclear medicine in the management of thyroid disease (English)

1 reference

19 August 2017

John Buscombe

1

1 reference

19 August 2017

Hassan Hirji

series ordinal

2

1 reference

19 August 2017

Caroline Witney-Smith

series ordinal

3

1 reference

19 August 2017

publication date

1 September 2008

1 reference

Expert Review of Anticancer Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

1425-1431

1 reference

Thyroid cancer in Luxembourg: a national population-based data report (1983-1999)

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Changing trends in incidence and mortality of thyroid cancer in Scotland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

The use of lithium carbonate in the preparation for definitive therapy in hyperthyroid patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Regional metastases in well-differentiated thyroid carcinoma: pattern of spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Radioiodine therapy after pretreatment with bexarotene for metastases of differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Gene therapy for thyroid cancer: current status and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Innovative strategies for the treatment of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

Targeted therapy in nuclear medicine--current status and future prospects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.9.1425

10.1586/14737140.8.9.1425

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference